Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 10, 2026OncoImmunologyOpen Access

Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

LFLorenzo FalchiMemorial Sloan Kettering Cancer CenterMHM L HutchingsUniversity of CopenhagenDTDavid TyborAbbVie (United States)

Discussion

Loading...

Member takes

Overview

Randomized trial compares epcoritamab plus lenalidomide and rituximab with usual care, indicating improved outcomes in relapsed follicular lymphoma.

Key Points

  • This research aims to compare the efficacy of epcoritamab combined with lenalidomide and rituximab against standard usual care in treating relapsed/refractory follicular lymphoma.
  • Adjusted comparative analysis using data from the phase 1b/2 EPCORE NHL-2 trial (NCT04663347; n=111) and COTA records (n=380).
  • Evaluated overall response, complete response, duration of response, progression-free survival, and overall survival between treatment arms.
  • Epcoritamab + R2 achieved an overall response rate of 96.9% versus 80.5% for R2/CIT (P < .001).
  • Complete response rate was 90.2% for epcoritamab + R2 compared to 55.1% for R2/CIT (P < .001).
  • Epcoritamab + R2 showed improved overall survival (HR, 0.33 [95% CI, 0.16-0.70]; P = .003) over R2/CIT.

Cite This Study

Falchi et al. (2026) studied this question.

synapsesocial.com/papers/6a508d536eeac72a437a0e31https://doi.org/10.1080/2162402x.2026.2691549
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma2025 · 14 citations
  2. 2Real‐world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B‐cell lymphoma by line of therapy2024 · 19 citations
  3. 3Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study2019 · 288 citations
  4. 4Follicular lymphoma: evolving therapeutic strategies2016 · 167 citations
  5. 5An evaluation of the impact of missing deaths on overall survival analyses of advanced non–small cell lung cancer patients conducted in an electronic health records database2019 · 58 citations